➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
McKesson
Dow
Harvard Business School
Johnson and Johnson

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,220,742


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,220,742
Title:Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Abstract: The present invention relates to enantiomerically pure compounds of general formula 1 ##STR00001## wherein the groups R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X.sup.- may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
Inventor(s): Lustenberger; Philipp (Warthausen, DE), Konetzki; Ingo (Warthausen, DE), Sieger; Peter (Mittelbiberach, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:11/128,032
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,220,742

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim STIOLTO RESPIMAT olodaterol hydrochloride; tiotropium bromide SPRAY, METERED;INHALATION 206756-001 May 21, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y TREATMENT OF RESPIRATORY COMPLAINTS ⤷  Free Forever Trial
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,220,742

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2004 024 454May 14, 2004

International Family Members for US Patent 7,220,742

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005243469 ⤷  Free Forever Trial
Brazil PI0511102 ⤷  Free Forever Trial
Canada 2562859 ⤷  Free Forever Trial
China 101133039 ⤷  Free Forever Trial
China 102827097 ⤷  Free Forever Trial
China 106146425 ⤷  Free Forever Trial
China 106995414 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Mallinckrodt
Colorcon
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.